- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Biogen adjusted profit rose in the first quarter on a small increase in total revenue. Sales of the biotech company's multiple sclerosis drugs remain flat.
Stock futures move higher on Tuesday, extending gains seen a day earlier, after a series of positive earnings results from the likes of DuPont, Novartis, and Rite Aid.
U.S. stock futures rise and European shares are mostly higher as global markets rally in the wake of Emmanuel Macron's victory in the first round of France's presidential elections.
When Biogen reports first-quarter earnings Tuesday, investors will be looking to see if Spinraza sales match or exceed $16 million consensus.